ATTACHMENT 3.1-A Page 46g

STATE: Minnesota Effective: April 1, 2024

TN: 24-0017 Approved: \_\_\_\_\_

Supersedes: 19-06, 12-10 (05-09, 04-09, 03-36)

## 12a. <u>Prescribed drugs</u> (continued)

- 4. The unit rebate amount is confidential and will not be disclosed except in accordance with §1927(b)(3)(D) of the Act.
- 5. A drug that the Department determines comes within its multi-state supplemental drug rebate program for Medicaid recipients as allowed by §1927, but for which a manufacturer has not signed a supplemental drug rebate agreement authorized by CMS, will be prior authorized.

Even if a manufacturer has not signed a supplemental drug rebate agreement, there is never prior authorization for any atypical antipsychotic drug prescribed for the treatment of adult mental illness if:

- there is no generically equivalent drug available; and
- the drug was initially prescribed for the recipient before July 1, 2003; or
- the drug is part of the recipient's current course of treatment.

Medicaid covers the following prescribed drugs not eligible for rebate:

- vitamins for adults with documented vitamin deficiencies
- vitamins for children under the age of seven and pregnant or nursing women

The State may enter into value-based contracts with manufacturers on a voluntary basis. These contracts will be executed on the model agreement entitled "Value-Based Supplemental Rebate Agreement" submitted to CMS on May 8, 2024, and authorized for use beginning April 1, 2024.

STATE: MINNESOTA ATTACHMENT 3.1-B Effective: April 1, 2024 Page 45g

TN: 24-0017 Approved: \_\_\_\_\_

Supersedes: 19-06, 12-19 (05-09, 04-09, 03-36)

## 12a. <u>Prescribed drugs</u> (continued)

4. The unit rebate amount is confidential and will not be disclosed except in accordance with §1927(b)(3)(D) of the Act.

5. A drug that the Department determines comes within its multi-state supplemental drug rebate program for Medicaid recipients as allowed by §1927, but for which a manufacturer has not signed a supplemental drug rebate agreement authorized by CMS, will be prior authorized.

Even if a manufacturer has not signed a supplemental drug rebate agreement, there is never prior authorization for any atypical antipsychotic drug prescribed for the treatment of adult mental illness if:

- there is no generically equivalent drug available; and
- the drug was initially prescribed for the recipient before July 1, 2003; or
- the drug is part of the recipient's current course of treatment.

Medicaid covers the following prescribed drugs not eligible for rebate:

- vitamins for adults with documented vitamin deficiencies
- vitamins for children under the age of seven and pregnant or nursing women

The State may enter into value-based contracts with manufacturers on a voluntary basis. These contracts will be executed on the model agreement entitled "Value-Based Supplemental Rebate Agreement" submitted to CMS on May 8, 2024, and authorized for use beginning April 1, 2024.